Squarepoint’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.02M | Sell |
6,752
-382,268
| -98% | -$178M | ﹤0.01% | 1890 |
|
|
2025
Q4 | $176M | Sell |
389,020
-218,816
| -36% | -$94.3M | 0.19% | 96 |
|
|
2025
Q3 | $238M | Buy |
607,836
+432,149
| +246% | +$181M | 0.24% | 71 |
|
|
2025
Q2 | $78.2M | Buy |
175,687
+168,792
| +2,448% | +$77.8M | 0.08% | 276 |
|
|
2025
Q1 | $3.34M | Sell |
6,895
-2,197
| -24% | -$1.02M | ﹤0.01% | 1702 |
|
|
2024
Q4 | $3.66M | Buy |
9,092
+1,162
| +15% | +$539K | ﹤0.01% | 1895 |
|
|
2024
Q3 | $3.69M | Sell |
7,930
-17,173
| -68% | -$8.25M | 0.01% | 1618 |
|
|
2024
Q2 | $11.8M | Sell |
25,103
-30,464
| -55% | -$13.2M | 0.02% | 855 |
|
|
2024
Q1 | $23.2M | Buy |
55,567
+34,157
| +160% | +$14.4M | 0.04% | 547 |
|
|
2023
Q4 | $8.71M | Sell |
21,410
-22,647
| -51% | -$8.37M | 0.02% | 1031 |
|
|
2023
Q3 | $15.3M | Buy |
44,057
+34,187
| +346% | +$12M | 0.04% | 576 |
|
|
2023
Q2 | $3.47M | Sell |
9,870
-2,994
| -23% | -$1.01M | 0.01% | 1299 |
|
|
2023
Q1 | $4.05M | Sell |
12,864
-30,633
| -70% | -$9.19M | 0.02% | 990 |
|
|
2022
Q4 | $12.6M | Buy |
+43,497
| New | +$13.3M | 0.05% | 411 |
|
|
2022
Q1 | – | Sell |
-49,545
| Closed | -$10.9M | – | 3585 |
|
|
2021
Q4 | $10.9M | Sell |
49,545
-104,211
| -68% | -$20.3M | 0.03% | 489 |
|
|
2021
Q3 | $27.9M | Buy |
153,756
+65,841
| +75% | +$12.9M | 0.08% | 228 |
|
|
2021
Q2 | $17.7M | Sell |
87,915
-46,326
| -35% | -$9.69M | 0.07% | 274 |
|
|
2021
Q1 | $28.8M | Buy |
134,241
+127,401
| +1,863% | +$28M | 0.17% | 120 |
|
|
2020
Q4 | $1.62M | Sell |
6,840
-58,448
| -90% | -$13.4M | 0.01% | 1051 |
|
|
2020
Q3 | $17.8M | Buy |
65,288
+34,443
| +112% | +$9.5M | 0.24% | 92 |
|
|
2020
Q2 | $8.96M | Buy |
30,845
+17,245
| +127% | +$4.68M | 0.14% | 192 |
|
|
2020
Q1 | $3.24M | Sell |
13,600
-80,957
| -86% | -$18.6M | 0.08% | 302 |
|
|
2019
Q4 | $20.7M | Buy |
94,557
+38,332
| +68% | +$7.76M | 0.12% | 139 |
|
|
2019
Q3 | $9.53M | Sell |
56,225
-6,264
| -10% | -$1.11M | 0.09% | 295 |
|
|
2019
Q2 | $11.5M | Sell |
62,489
-126,119
| -67% | -$22M | 0.11% | 223 |
|
|
2019
Q1 | $34.7M | Buy |
188,608
+61,694
| +49% | +$11.4M | 0.37% | 47 |
|
|
2018
Q4 | $21M | Buy |
126,914
+55,522
| +78% | +$9.62M | 0.24% | 82 |
|
|
2018
Q3 | $13.8M | Buy |
71,392
+50,892
| +248% | +$9.06M | 0.16% | 166 |
|
|
2018
Q2 | $3.48M | Sell |
20,500
-92,729
| -82% | -$14.4M | 0.05% | 481 |
|
|
2018
Q1 | $18.5M | Buy |
+113,229
| New | +$18.5M | 0.29% | 80 |
|
|
2017
Q4 | – | Sell |
-86,597
| Closed | -$13.2M | – | 2363 |
|
|
2017
Q3 | $13.2M | Sell |
86,597
-44,680
| -34% | -$6.73M | 0.25% | 93 |
|
|
2017
Q2 | $16.9M | Buy |
+131,277
| New | +$15.8M | 0.33% | 55 |
|
|
2017
Q1 | – | Sell |
-7,093
| Closed | -$523K | – | 1938 |
|
|
2016
Q4 | $523K | Buy |
+7,093
| New | +$577K | 0.02% | 797 |
|
|
2016
Q3 | – | Sell |
-3,302
| Closed | -$284K | – | 1277 |
|
|
2016
Q2 | $284K | Sell |
3,302
-5,308
| -62% | -$459K | 0.02% | 764 |
|
|
2016
Q1 | $684K | Buy |
+8,610
| New | +$779K | 0.05% | 503 |
|
|
2015
Q3 | – | Sell |
-1,988
| Closed | -$245K | – | 593 |
|
|
2015
Q2 | $245K | Buy |
+1,988
| New | +$251K | 0.08% | 330 |
|
Other funds holding VRTX
VCM
VPM
Squarepoint's VRTX Position: Q1 2026 in Review
Squarepoint reduced its Vertex Pharmaceuticals (VRTX) stake by 98% in Q1 2026, selling an estimated $178M and leaving 6,752 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1890.
Squarepoint first reported a position in VRTX in Q2 2015 and has held it in 36 quarters since. The position peaked at $238M in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Squarepoint held 6,752 shares of Vertex Pharmaceuticals worth $3.02M as of Q1 2026.
- Squarepoint sold 382,268 Vertex Pharmaceuticals shares in Q1 2026, an estimated $178M.
- Vertex Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1890 holding.
- Squarepoint first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 36 quarters since.
- Squarepoint's Vertex Pharmaceuticals position peaked at $238M in Q3 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.